MPI Research is proud to announce the addition of site specific absorption and metabolism assays to its DMPK service line. Many pharmaceutical and biotechnology companies struggle to develop drug candidate formulations that achieve desired target organ delivery or bioavailability. Site specific delivery studies can be instrumental in overcoming these challenges.

The enhanced ability to perform test article dosing and sampling via surgical and non-surgical techniques, at specific sites such as the duodenum, jejunum, colon, portal and hepatic veins and arteries allows the staff at MPI Research to help determine the site and rate of absorption for sponsors. This information can be critical in formulation development and optimizing drug delivery. These same techniques are important tools in mechanistic studies to determine the sites of 1 st and 2nd pass metabolism. Most of these models have now been maintained for up to one year allowing MPI Research to run these studies in multiple species meeting Sponsor needs for individual studies or larger screening programs.

Mary Sherman, Ph.D., Director of ADME for MPI Research commented, “The addition of these assays underscores the commitment of MPI Research to the DMPK service line and being responsive to our Sponsors. This is one more example of our focus on helping our clients bring new and better therapeutics to the marketplace”.

MPI Research exists to provide comprehensive non-clinical research that meets the requirements of pharmaceutical, medical device, animal health and chemical companies as well as governmental agencies as we partner together to bring safer, healthier products to the world. MPI Research employees specialize in a wide variety of scientific disciplines including toxicology, pharmacology, metabolism, pathology, clinical pathology, reproductive and developmental biology, veterinary science, neuroscience, experimental therapeutics, immunotoxicology, analytical chemistry, computer science, regulatory science, and statistics.

Home | News